<DOC>
	<DOCNO>NCT01412957</DOCNO>
	<brief_summary>The purpose study evaluate benefit panitumumab addition best supportive care compare best supportive care alone patient chemorefractory wild-type KRAS ( Kirsten rat sarcoma viral oncogene homolog ) metastatic colorectal cancer .</brief_summary>
	<brief_title>Comparison Survival Benefit Panitumumab With Supportive Care Best Supportive Care Alone Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis metastatic colorectal cancer ( CRC ) Wildtype ( without mutation codon 12 13 ) KRAS gene tumor tissue confirm central laboratory Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 At least 1 measurable nonmeasurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 guideline . Treatment failure ( defined failure due either disease progression [ clinical radiological ] toxicity [ treatment intolerance ] ) prior regimen contain irinotecan metastatic disease prior regimen contain oxaliplatin metastatic disease . Oxaliplatin irinotecan may administer sequentially combination . Disease relapse within 6 month complete adjuvant chemotherapy ( either irinotecan oxaliplatin contain regimen ) also consider treatment failure prior regimen metastatic disease Must previously receive thymidylate synthase inhibitor ( eg , fluorouracil , capecitabine , raltitrexed , fluorouraciluracil ) point treatment CRC Man woman least 18 year age Adequate hematologic , renal , hepatic metabolic function Negative pregnancy test within 72 hour randomization ( woman childbearing potential ) Subject subject 's legally acceptable representative provide informed consent . Other protocolspecified criterion may apply Symptomatic brain metastasis require treatment History another primary cancer within 5 year randomization Prior antiepidermal growth factor receptor ( EGFR ) antibody therapy ( eg , panitumumab cetuximab ) treatment small molecule EGFR inhibitor ( eg , gefitinib , erlotinib , lapatinib ) Antitumor therapy ( eg , chemotherapy , hormonal therapy , immunotherapy , antibody therapy ) within 21 day randomization Radiotherapy within 14 day randomization . Exclusion Criteria correct QT ( QTc ) Evaluation Subpart Study : Prolongation QT/QTc interval &gt; 450 millisecond screen Other protocolspecified criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Best Supportive Care</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Chemorefractory</keyword>
	<keyword>Wild-type KRAS</keyword>
	<keyword>Overall Survival</keyword>
	<keyword>Phase 3</keyword>
</DOC>